Completed PHASE2 INTERVENTIONAL 2-arm NCT00170677

Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

Sponsor: North Eastern German Society of Gynaecological Oncology

Interventions Topotecan

Updated 6 times since 2017 Last updated: May 13, 2014 Started: Sep 30, 2005 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovarian Cancer, this trial is completed. The trial is conducted by North Eastern German Society of Gynaecological Oncology and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2020 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

North Eastern German Society of Gynaecological Oncology

Data source: North Eastern German Society of Gynaecological Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany